Flag of the European Union EU Clinical Trials Register Help

Clinical trials for lung cancer

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
    • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.

    The EU Clinical Trials Register currently displays   40995   clinical trials with a EudraCT protocol, of which   6701   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,466 result(s) found for: lung cancer. Displaying page 1 of 74.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2009-012607-26 Sponsor Protocol Number: MIMEB Start Date*: 2009-12-10
    Sponsor Name:University of Cologne
    Full Title: MIMEB - Molecular Imaging with erlotinib and bevacizumab. A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT-PET and DCE-MRI for Early Prediction of Non-Progression in Patients with Adv...
    Medical condition: Patients with Advanced Non Squamous Cell Non Small Cell Lung Cancer (NSCLC), first-line.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10025054 Lung cancer non-small cell stage IIIB LLT
    12.0 10025055 Lung cancer non-small cell stage IV LLT
    12.0 10029515 Non-small cell lung cancer recurrent PT
    12.0 10029521 Non-small cell lung cancer stage IIIB PT
    12.0 10029522 Non-small cell lung cancer stage IV PT
    12.0 10029521 Non-small cell lung cancer stage IIIB LLT
    12.0 10029522 Non-small cell lung cancer stage IV LLT
    12.0 10050017 Lung cancer metastatic LLT
    12.0 10059515 Non-small cell lung cancer metastatic LLT
    12.0 10061873 Non-small cell lung cancer LLT
    12.0 10066490 Progression of non-small cell lung cancer LLT
    12.0 10050017 Lung cancer metastatic PT
    12.0 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005245-37 Sponsor Protocol Number: M06-880 Start Date*: 2008-04-17
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: An Open-Label, Randomized, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
    Medical condition: Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    9.1 10029514 Non-small cell lung cancer NOS LLT
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    9.1 10029516 Non-small cell lung cancer stage 0 LLT
    9.1 10029517 Non-small cell lung cancer stage I LLT
    9.1 10029518 Non-small cell lung cancer stage II LLT
    9.1 10029519 Non-small cell lung cancer stage III LLT
    9.1 10029520 Non-small cell lung cancer stage IIIA LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    9.1 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) SE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001005-85 Sponsor Protocol Number: ATX-NS-001 Start Date*: 2021-07-06
    Sponsor Name:Achilles Therapeutics UK Limited
    Full Title: An open label, multi-centre, phase I/IIa study evaluating the safety and clinical activity of neoantigen reactive T cells in patients with advanced non-small cell lung cancer.
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001245 Adenosquamous cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001246 Adenosquamous cell lung cancer NOS LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001247 Adenosquamous cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001251 Adenosquamous cell lung cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001252 Adenosquamous cell lung cancer stage IIIA LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001253 Adenosquamous cell lung cancer stage IIIB LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001254 Adenosquamous cell lung cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023774 Large cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069730 Large cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023775 Large cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023779 Large cell lung cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023780 Large cell lung cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025044 Lung cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050017 Lung cancer metastatic PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025048 Lung cancer non-small cell recurrent LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025052 Lung cancer non-small cell stage III LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029514 Non-small cell lung cancer NOS LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066490 Progression of non-small cell lung cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025053 Lung cancer non-small cell stage IIIA LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025054 Lung cancer non-small cell stage IIIB LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003790-18 Sponsor Protocol Number: N16HYP Start Date*: 2017-04-28
    Sponsor Name:The Netherlands Cancer Institute
    Full Title: Feasibility trial on combination of platinum doublets and hypofractionated radiotherapy for locally-advanced stage and / or inoperable non-small cell lung carcinoma
    Medical condition: Locally advanced non-small cell lung carcinoma stage III or inoperable stage II
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025044 Lung cancer LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025053 Lung cancer non-small cell stage IIIA LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025054 Lung cancer non-small cell stage IIIB LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025051 Lung cancer non-small cell stage II LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025052 Lung cancer non-small cell stage III LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001252 Adenosquamous cell lung cancer stage IIIA LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001253 Adenosquamous cell lung cancer stage IIIB LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025060 Lung cancer stage II LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025061 Lung cancer stage III LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001255 Adenosquamous cell lung cancer stage unspecified LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001246 Adenosquamous cell lung cancer NOS LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029518 Non-small cell lung cancer stage II PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000570-22 Sponsor Protocol Number: 20060441 Start Date*: 2008-01-07
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-Blind, Trial of AMG 745 or Placebo for the Treatment of Cachexia in Subjects with Non-Small Cell Lung Cancer
    Medical condition: Muscle cachexia due to non-small cell lung cancer (NSCLC).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064015 Cancer cachexia LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007696-16 Sponsor Protocol Number: TOGA 0601 Start Date*: 2008-06-02
    Sponsor Name:TOGA Thoracic Oncology Group Antwerp
    Full Title: Low molecular weight heparin in advanced non small cell lung cancer (NSCLC): a randomized open label phase III study evaluating the effect of enoxaparin (Clexane) on survival and symptom control in...
    Medical condition: Non Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025054 Lung cancer non-small cell stage IIIB LLT
    9.1 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005614-29 Sponsor Protocol Number: CC-486-NSCL-001 Start Date*: 2015-11-19
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2 multicenter, randomized, placebo controlled, double-blind study to assess the safety and efficacy of CC-486 (oral azacitidine) in combination with pembrolizumab (MK-3475) versus pembroliz...
    Medical condition: Second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC).
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066490 Progression of non-small cell lung cancer LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Ongoing) ES (Completed) GR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-007107-32 Sponsor Protocol Number: M10-301 Start Date*: 2009-07-31
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin /Paclitaxel in Combination with ABT-869 Versus Carboplatin/Paclitaxel Alone in Subjects with Advanced or Metastatic Non-S...
    Medical condition: Non small cell lung cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029514 Non-small cell lung cancer NOS LLT
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    9.1 10029516 Non-small cell lung cancer stage 0 LLT
    9.1 10029517 Non-small cell lung cancer stage I LLT
    9.1 10029518 Non-small cell lung cancer stage II LLT
    9.1 10029519 Non-small cell lung cancer stage III LLT
    9.1 10029520 Non-small cell lung cancer stage IIIA LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV PT
    9.1 10059515 Non-small cell lung cancer metastatic PT
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-000659-23 Sponsor Protocol Number: 220365-2017 Start Date*: 2017-10-11
    Sponsor Name:Aarhus University Hospital
    Full Title: A Safety and feasibility study of standard dosing day 1 carboplatin AUC 5 every 3rd weeks with daily Navelbine® 20/30mg (oral) during 4 cycles (12 weeks) for the treatment of advanced NSCLC; A feas...
    Medical condition: Patients with metastatic or locally advanced Non-small-cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000015855 10025044 Lung cancer LLT
    20.0 100000015841 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005942-22 Sponsor Protocol Number: MK8669-021 Start Date*: 2009-01-15
    Sponsor Name:MERCK & CO., INC.
    Full Title: A Randomized Discontinuation Phase II Trial of Deforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients with KRAS Mutations.
    Medical condition: Non-Small Cell Lung Cancer (NSCLC) Patients with KRAS Mutations
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-005294-35 Sponsor Protocol Number: ELDERLY-NEXT Start Date*: 2009-02-26
    Sponsor Name:AZIENDA USL 6 LIVORNO ZONA LIVORNESE
    Full Title: Multicenter Phase II study of Sequential Chemotherapy with Cisplatin/Gemcitabine Followed by Docetaxel in Elderly Advanced Non-Small-Cell Lung Cancer (NSCLC) patients
    Medical condition: elderly advanced NSCLC patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001160 LLT
    9.1 10001162 LLT
    9.1 10025031 LLT
    9.1 10001160 LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002539-25 Sponsor Protocol Number: ATOM 019 Start Date*: 2004-12-10
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI UDINE
    Full Title: Randomized phase II trial of second-line chemotherapy with oxaliplatin and docetaxel vs. docetaxel in patients with advanced non-small cell lung cancer (NSCLC)
    Medical condition: Second-line chemotherapy in advanced non small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10059515 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018614-70 Sponsor Protocol Number: D791AC00014 Start Date*: 2010-09-03
    Sponsor Name:AstraZeneca AB
    Full Title: An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA™) as First line Treatment in Caucasian Patients, who have Epidermal Gr...
    Medical condition: Non Small Cell Lung Cancer.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025053 Lung cancer non-small cell stage IIIA LLT
    12.1 10025054 Lung cancer non-small cell stage IIIB LLT
    12.1 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) ES (Completed) GB (Completed) FR (Completed) IT (Ongoing) NO (Completed) HU (Ongoing) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-002192-33 Sponsor Protocol Number: TRADE-hypo Start Date*: 2020-02-06
    Sponsor Name:Institut für Klinische Krebsforschung IKF GmbH
    Full Title: Thoracic Radiotherapy plus Durvalumab in Elderly and/or frail NSCLC stage III patients unfit for chemotherapy- Employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy
    Medical condition: unresectable stage III NSCLC (Non–small-cell lung cancer)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025052 Lung cancer non-small cell stage III LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025054 Lung cancer non-small cell stage IIIB LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025053 Lung cancer non-small cell stage IIIA LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000104-42 Sponsor Protocol Number: U31287-A-U201E Start Date*: 2013-06-14
    Sponsor Name:DAIICHI SANKYO DEVELOPMENT LTD.
    Full Title: Open-label, Non-randomized Study of U3-1287 in Combination with Erlotinib in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC) - Extension
    Medical condition: Treatment for advanced or metastatic NSCLC in combination with erlotinib in subjects who are epidermal growth factor receptor (EGFR) treatment naïve after failure of at least one prior chemotherapy...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000711-85 Sponsor Protocol Number: MEF4984g Start Date*: 2011-10-17
    Sponsor Name:Genentech, Inc
    Full Title: A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF MEGF0444A IN COMBINATION WITH CARBOPLATIN, PACLITAXEL AND BEVACIZUMAB IN PATIENTS ...
    Medical condition: ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025054 Lung cancer non-small cell stage IIIB LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025052 Lung cancer non-small cell stage III LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025048 Lung cancer non-small cell recurrent LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025051 Lung cancer non-small cell stage II LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025046 Lung cancer cell type unspecified stage IV LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025053 Lung cancer non-small cell stage IIIA LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025050 Lung cancer non-small cell stage I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003690-40 Sponsor Protocol Number: 944/08 Start Date*: 2008-06-16
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Low-doses radiotherapy and concomitant chemotherapy with pemetrexed in progression desease NSCLC: a dose-descalation phase II study
    Medical condition: advanced and/or metastatic NSCLC
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001436-10 Sponsor Protocol Number: INCB18424-266 Start Date*: 2015-02-26
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non–Small C...
    Medical condition: Nonsquamous NSCLC that is Stage IIIB, Stage IV, or recurrent
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DK (Prematurely Ended) ES (Prematurely Ended) NL (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003715-38 Sponsor Protocol Number: D4190C00006 Start Date*: 2016-05-12
    Sponsor Name:MedImmune LLC
    Full Title: A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-small Cell Lung Cancer
    Medical condition: Locally advanced or metastatic squamous or nonsquamous non- small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066490 Progression of non-small cell lung cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) DE (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-024468-16 Sponsor Protocol Number: BO25460 Start Date*: 2011-06-29
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized, double-blind, placebo-controlled Phase III study of first-line maintenance Tarceva vs Tarceva at the time of disease progression in patients with advanced non-small cell lung cancer (...
    Medical condition: Advanced (Stage IIIB or IV) NSCLC previously treated with 4 cycles of a platinum-based chemotherapy (for Traceva®).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) CZ (Completed) LV (Completed) LT (Completed) NL (Completed) FR (Ongoing) BG (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands     Legal notice
    EMA HMA